Cervical Cancer OXCOG podcast Flashcards
UK Stats for cervical cancer
Cases per year in UK
Case per 100
3200 in UK
3rd most common gynae cancer in developed (Endometrial, Ovarian)
lifetime risk of developing cervical 7 in 1000 women UK
In developing countries 2nd most common cancer, 3rd most common cancer death (most common gnar cancer worldwide)
HPV is detected in what % cervical cancers?
99.7%
What are the most common types of cervical cancer?
Squamous Cell carcinoma 70%
Adenocarcinoma 25%
RF cervical cancer
HPV related
- Early onset sexual activity
- Multiple sexual partners
- High risk sexual partner
- Hx STIs
- immunosupression
Non HPV related
- Low socioeconomic status
- COCP > 5years, background after 10 years
- Cigarette smoking - squamous cell not adenocarcinoma
- Genetics
How many HPV are oncogenic
15 of the 40 HPV
HPV 16&18 in 70% of cervical cancers
How many sexual active patient have HPV at some point
75-85%, most people clear the virus
Squamous cell carcinoma - HPV subtypes
16 60%
18 13%
58/33 5%
Adenocarcioma cell carcinoma - HPV
16 36%
18 37%
45 5%
Presenting Sx cervical cancers
Asymptomatic
IMB/PCB/PMB
Dyspareuniria
Abnormal vaginal discharge
Abnormal speculum
Haematuia
Urinay incontince
Loin pain (hydronephrosis)
Weight loss
Change bladder/bowel
Peak age incidence of cervical carcinoma
25-29yrs
rare <25yrs
Cervical cancer %
localised/regional/mets at diagnosis
44% localised
34% regional
15% distant mets
How to Dx cervical cancer
Colposcopy and biopsy (punch Bx, multiple or LLETZ)
Where does cervical cancer spread locally
Vagina
Parametrium
Uterosacral ligaments
Bladder/rectum/para aorta lymph nodes
Where does cervical cancer spread distantly
Bone, liver, lungs
FIGO Stage 1a
1a1
1a2
1a Microscopic <5mm
1a1 Stromal <3mm
1a2 Stromal 3-5mm
Figo Stage 1b
1b1
1b2
1b3
Figo Stage 1b Deepest invasion >5mm
1b1 Dimension <2cm
1b2 Dimension 2-4cm
1b3 Dimension >4cm
FIGO Stage 2
Metastasised to uterus not not lower 1/3 vagina or side wall
Figo Stage 2a
2a1
2a2
Figo Stage 2a: upper 2/3 vagina, no parametrium
2a1 <4cm dimension
2a2 >4cm dimension
FIGO stage 2b
Parametrial invasion no side wall
FIGO stage 3
Further local spread
Lower 1/3
Pelvic side wall
Hydropnephrosis
Involves pelvic or para-aortic lymph noces
FIGO
3a
3b
3a Lower 1/3 vagina
3b Pelvic side wall, hydronephrosis, non functioning kidney
FIGO stage 3c
3c1
3c2
FIGO stage 3c Local Lymph nocdes
3c1 Pelvic
3c2 para-aortic
FIGO stage 4
4a
4b
Beyond true pelvis, involved Bx proved mucosa bladder/rectum
4a Adjacent pelvic organs
4b distant organs
5 year surgical stage 1 cervical cancer
95%
5 year surgical stage 2 cervical cancer
70%
5 year surgical stage 3 cervical cancer
40%
5 year surgical stage 5 cervical cancer
15%
What cross sectional imaging can be used pre-op for cancers above 1a
MRI > CT - diffusion weighted increases sensitivity
More accurate for staging
7-10 days after biopsy (prevent artefact)
High negative predictive value bladder/bowel involvement
Chest imaging - plain CXR
If nodal disease suspected → FDG PET CT (If >1b2)
Clinical examination also essential
Gold standing for assessing lymph node mets
Sentinal lymph node biopsy - surgically
Which cancers used Sentinal lymph node biopsy for staging?
Breast, vulval and cervical
Helps assess for chemo-radiotherapy
NPP 95%
Surgical management for Stage 1a1 cervical cancer
Cold knife/Loop Coneisation with clear margins for cancer and dysplasia
Non-fragmented speculum
When completed family/fertility not desired → simple hysterectomy
Complications from conisation (cone Bx, LLETZ)
Cervical imcompentence
Stenosis
Pre term delivery
Surgical management Stage 1a2-1b2
Radical hysterectomy + BSO + pelvic lymphdenectomy
Fertility preservation - conisation/trachelectomy with clear margins
If those with adneocarcinoma what else should they be counselled on?
BSO - risk of recurrence in adenxa
Surgical options for fertility preservation for cervical cancer up to stage 1b1
Radical trachelectomy + cerclage + BL lymphdectomy +/- genital node Bx
consider up to 1b2
When is adjacent chemo radiotherapy offered
Higher risk factors
Unclear margins
+ve pelvic lymph nodes
Parametrial spread
Treatment for local spread 1b3 onwards
Chemoradiotherapy
External beam radiation, bracytherapy
Cisplatin chemotherapy
When is pelvic excenteration offered
Some cases 4a disease
Neoadjuvant chemotherapy before surgery or radiation